Cereno Scientific strengthens its clinical expertise, establishes Scientific Advisory Board
Cereno Scientific today announced the establishment of a Scientific Advisory Board, whose purpose is to strengthen the transfer of knowledge from academic research into a business environment. Dr. Bertram Pitt, a professor at the University of Michigan School of Medicine with long-standing experience and a strong reputation in the field of cardiovascular diseases, has accepted the offer to become the chair of the board.
“By establishing a Scientific Advisory Board, we are strengthening the company’s competence and clinical expertise, which is important for quality assurance in our clinical development of drugs for cardiovascular diseases. Dr. Bertram Pitt has a solid and respected reputation in cardiovascular medicine internationally, and I am pleased to welcome him as the chair of our Scientific Advisory Board,” says Cereno Scientific CEO Sten R. Sörensen.
Dr. Pitt is Professor Emeritus in Medicine at the Cardiology Division of the University of Michigan School of Medicine. He has been a leader in designing and implementing a series of well-known major international randomized clinical trials that led to new treatments of various cardiovascular diseases including SOLVD prevention and SOLVD treatment, TRANSFORM and SPIRRIT, RALES, EPHESUS, EMPHASIS-HF, ELITE 1 and 2, FIGARO and SOLOIST. Dr. Pitt has received life time achievement awards for his work from the Heart Failure Society of America and the European Heart Failure Society, as well as the Herrick Award from the American Heart Association.
“CS1 provides a new opportunity to safely prevent thrombosis but in contrast to other currently available antithrombotic drugs it has additional potential that we are excited about. For example, not only could it prevent thromboembolic events but could also prevent the development of atrial fibrillation,” says Dr. Bertram Pitt.
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on March 11, 2019.